DRMAW Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: ACCESS Newswire - Mentions: DRMA

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

2 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

2 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

2 months ago - By: Virtual Investor Conferences - Mentions: DRMA

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

3 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

3 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

7 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

8 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

5 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

7 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

8 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

9 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

10 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata to Present on BioPub on January 31, 2025

10 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

10 months ago - By: ACCESS Newswire - Mentions: DRMA

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

a year ago - By: Virtual Investor Conferences - Mentions: DRMA

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

2 years ago - By: Benzinga

DERMATA THERAPEUTICS -CW26 (DRMAW) Stock News

DRMAW Latest News, Press Relases and Analysis

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata to Present on BioPub on January 31, 2025

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Why Dermata Therapeutics Stock Took Off After-Hours